Traws Pharma, Inc. (NASDAQ:TRAW) Stock Has Average Price Target of $1.00 According to Brokerages

Shares of Traws Pharma, Inc. (NASDAQ:TRAW – Get Free Report) have been assigned an average rating of “Reduce” from the five ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $1.00.

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday, August 26th. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a report on Tuesday, August 18th.

Get Our Latest Stock Analysis on TRAW

Traws Pharma Price Performance

Traws Pharma stock opened at $0.26 on Thursday. The business’s fifty day moving average is $0.42 and its two-hundred day moving average is $1.06. Traws Pharma has a 52 week low of $0.22 and a 52 week high of $3.23.

Traws Pharma (NASDAQ:TRAW – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. On average, equities analysts expect that Traws Pharma will post -1.20 earnings per share for the current fiscal year.

Traws Pharma Company Profile

(Get Free Report)

Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.

Further Reading

Analyst Recommendations for Traws Pharma (NASDAQ:TRAW)

Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.